TY - JOUR
T1 - Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial
AU - Shindiapina, Polina
AU - Pietrzak, Maciej
AU - Seweryn, Michal
AU - McLaughlin, Eric
AU - Zhang, Xiaoli
AU - Makowski, Mat
AU - Ahmed, Elshafa Hassan
AU - Schlotter, Sarah
AU - Pearson, Rebecca
AU - Kitzler, Rhonda
AU - Mozhenkova, Anna
AU - Le-Rademacher, Jennifer
AU - Little, Richard F.
AU - Akpek, Gorgun
AU - Ayala, Ernesto
AU - Devine, Steven M.
AU - Kaplan, Lawrence D.
AU - Noy, Ariela
AU - Popat, Uday R.
AU - Hsu, Jack W.
AU - Morris, Lawrence E.
AU - Mendizabal, Adam M.
AU - Krishnan, Amrita
AU - Wachsman, William
AU - Williams, Nita
AU - Sharma, Nidhi
AU - Hofmeister, Craig C.
AU - Forman, Stephen J.
AU - Navarro, Willis H.
AU - Alvarnas, Joseph C.
AU - Ambinder, Richard F.
AU - Lozanski, Gerard
AU - Baiocchi, Robert A.
N1 - Publisher Copyright:
© Copyright © 2021 Shindiapina, Pietrzak, Seweryn, McLaughlin, Zhang, Makowski, Ahmed, Schlotter, Pearson, Kitzler, Mozhenkova, Le-Rademacher, Little, Akpek, Ayala, Devine, Kaplan, Noy, Popat, Hsu, Morris, Mendizabal, Krishnan, Wachsman, Williams, Sharma, Hofmeister, Forman, Navarro, Alvarnas, Ambinder, Lozanski and Baiocchi.
PY - 2021/9/3
Y1 - 2021/9/3
N2 - We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melphalan conditioning) at 56, 180, and 365 days post-AHCT, and 71 healthy control subjects. Principal component analysis showed that immune cell composition in HIV(+) and HIV(-) AHCT recipients clustered away from healthy controls and from each other at each time point, but approached healthy controls over time. Unsupervised feature importance score analysis identified activated T cells, cytotoxic memory and effector T cells [higher in HIV(+)], and naïve and memory T helper cells [lower HIV(+)] as a having a significant impact on differences between HIV(+) AHCT recipient and healthy control lymphocyte composition (p<0.0033). HIV(+) AHCT recipients also demonstrated lower median absolute numbers of activated B cells and lower NK cell sub-populations, compared to healthy controls (p<0.0033) and HIV(-) AHCT recipients (p<0.006). HIV(+) patient T cells showed robust IFNγ production in response to HIV and EBV recall antigens. Overall, HIV(+) AHCT recipients, but not HIV(-) AHCT recipients, exhibited reconstitution of pro-inflammatory immune profiling that was consistent with that seen in patients with chronic HIV infection treated with antiretroviral regimens. Our results further support the use of AHCT in HIV(+) individuals with relapsed/refractory lymphoma.
AB - We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melphalan conditioning) at 56, 180, and 365 days post-AHCT, and 71 healthy control subjects. Principal component analysis showed that immune cell composition in HIV(+) and HIV(-) AHCT recipients clustered away from healthy controls and from each other at each time point, but approached healthy controls over time. Unsupervised feature importance score analysis identified activated T cells, cytotoxic memory and effector T cells [higher in HIV(+)], and naïve and memory T helper cells [lower HIV(+)] as a having a significant impact on differences between HIV(+) AHCT recipient and healthy control lymphocyte composition (p<0.0033). HIV(+) AHCT recipients also demonstrated lower median absolute numbers of activated B cells and lower NK cell sub-populations, compared to healthy controls (p<0.0033) and HIV(-) AHCT recipients (p<0.006). HIV(+) patient T cells showed robust IFNγ production in response to HIV and EBV recall antigens. Overall, HIV(+) AHCT recipients, but not HIV(-) AHCT recipients, exhibited reconstitution of pro-inflammatory immune profiling that was consistent with that seen in patients with chronic HIV infection treated with antiretroviral regimens. Our results further support the use of AHCT in HIV(+) individuals with relapsed/refractory lymphoma.
KW - Hodgkin lymphoma (HL)
KW - Non-Hodgkin lymphoma
KW - hematopoeietic stem cell transplantation
KW - human immunodeficiency virus (HIV)
KW - multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85115152254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115152254&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2021.700045
DO - 10.3389/fimmu.2021.700045
M3 - Article
C2 - 34539628
AN - SCOPUS:85115152254
SN - 1664-3224
VL - 12
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 700045
ER -